Blood Podcast

American Society of Hematology

The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.

  1. hace 16 h

    IV Iron Risks and Low-Dose AML Gains

    In this week's episode, Blood editor Dr. James Griffin interviews Drs. Heinz Zoller and Raul Ribeiro on their latest articles published in Blood. Dr. Zoller discusses "Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia", and how these findings support consideration of alternative IV iron formulations that provide similar efficacy without risk of skeletal complications.  Dr. Ribeiro discusses "A low-versus standard-dose regimen an induction for AML: a multicenter, randomized noninferiority trial" and how the low-dose regimen is associated with fewer toxicities, faster hematologic recovery, and reduced health care costs, suggesting a feasible treatment strategy for resource-limited settings.

    25 min

  2. 25 jun

    Orca-T for GVHD–free survival and Understanding VEXAS anemia

    In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Everett Meyer and Olivier Hermine on their latest articles published in volume 147 issue 11 of Blood. Dr. Everett Meyer discusses "Orca-T vs allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial" which demonstrated that Orca-T showed superior chronic GVHD–free survival compared to the control arm (78.0% vs 38.4%, P .001) and lower nonrelapse mortality (3.4% vs 13.2%, P = .03). Dr. Olivier Hermine shares insights from "VEXAS anemia is a mosaic erythroblastopenia" which proposes that VEXAS syndrome–associated anemia should be considered as a mosaic erythroblastopenia, in which the severity of anemia is influenced by the quality and quantity of the UBA1–wild-type compartment.

    23 min

  3. 18 jun

    Treating AML, Before and After Relapse

    In this episode, Blood editor Dr. Laura Michaelis interviews Drs. Nigel Russell and Uwe Platzbecker on their articles published in volume 147 issue 10 of Blood. Dr. Russell discuses "CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non–adverse-risk AML: the NCRI AML18 trial" where a large randomized trial demonstrated that DA-GO2 provided greater overall survival as compared to CPX-351, and that further studies should compare DA-GO2 to lower-intensity venetoclax-based regimens. Dr. Platzbecker shares insights from the first prospective study to evaluate the clinical impact of early therapeutic intervention for MRD in "Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial" demonstrating potential therapies for patients to achieve and maintain remission.

    16 min

  4. 11 jun

    Future Directions in Relapsed and Refractory Large B-cell Lymphoma

    In this week's episode, Blood editor Dr. Philippe Armand interviews Drs. Manali Kamdar and Nancy L. Bartlett on their latest review article published in Blood titled “From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma”. They discuss the how the advent of chimeric antigen receptor T cells, antibody-drug conjugates, and bispecific antibodies all show major increases in efficacy over legacy chemotherapy-based regimens. They also share their insights on how to transform treatment paradigms in light of these breakthroughs.

    25 min
  5. Review Series on Clonal Tracking in Hematopoiesis

    4 jun

    Review Series on Clonal Tracking in Hematopoiesis

    In this Review series episode, Blood associate editor Dr. Diane Krause interviews contributing authors from the Review Series on Clonal tracking in Hematopoiesis published in volume 147 issue 23 of Blood. Dr. Alejo E. Rodriguez-Fraticelli speaks to the development of his paper, "Clonal tracing of blood stem cells across mouse and human lifespans”, which provides a detailed overview of the experimental approaches that make clonal analysis possible, and which approaches are most appropriate to use to address specific questions. Dr. Shalin H. Naik speaks about how different clonal tracking approaches have been used to address the central question of clonal fate specification of stem and progenitor cells to specific lineages in “The evolution of hematopoietic models through a clonal lens”. Finally, Dr. Federico Gaiti speaks about “Methylation-based lineage tracing in cancer”, which takes these ideas into the context of cancer, focusing on how DNA methylation can be used to reconstruct clonal relationships.

    30 min

  6. 28 may

    New Approaches: Marstacimab Therapy and HLH Biomarkers

    In this week's episode, Blood editor Dr. James Griffin interviews Drs. Johnny Mahlangu and Joseph Rocco on their articles published in volume 147 issue 9 of Blood.  Dr. Mahlangu discusses study details and next steps from "Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial" which shows that bleeding was reduced by 93% with subcutaneous marstacimab. Dr. Rocco shares the development behind "CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis", and the insights gained from measuring a new surrogate marker of IFN-γ activity predicting severity and mortality.

    18 min
  7. Review Series on Hemophagocytic Lymphohistiocytosis (HLH)

    21 may

    Review Series on Hemophagocytic Lymphohistiocytosis (HLH)

    In this episode, Blood deputy editor Dr. Helen Heslop interviews contributing  authors from the Blood review series on hemophagocytic lymphohistiocytosis. Drs. Nancy Berliner and Joanne Hsu join to provide insight on their paper, “Hemophagocytic lymphohistiocytosis in adults” discussing the importance of prompt diagnosis and treatment in this high-mortality disorder, and highlight emerging agents designed to modulate disease progression. Drs. Carl Allen and Bethany Verkamp reimagine diagnostic criteria through a threshold model in “Pediatric hemophagocytic lyphohistiocytosis: current conceptualization, diagnosis, and treatment”, in order to provide individualized therapies with the goal of addressing the combined influence of genetic susceptibility and environmental triggers.

    16 min

  8. 14 may

    IBD augmentation of CHIP and Platelet mTOR's impact on Cerebral Malaria

    In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Reuben Kapur and Robert Campbell on their latest articles published in Blood. This episode highlights two groundbreaking studies exploring how inflammation drives serious blood and immune-related diseases. In the first interview, Dr. Kapur discusses how inflammatory bowel disease (IBD) can both promote and worsen clonal hematopoiesis of indeterminate potential (CHIP), with large-scale human data and mouse models identifying REF1 as a key mediator and potential therapeutic target. The second segment features Dr. Campbell, who explains how heme released during malaria infection activates platelet mTOR signaling, intensifying cerebral malaria and suggesting new avenues for platelet-targeted treatments. Together, the conversations reveal how inflammatory pathways and immune signaling contribute to disease progression while opening the door to novel precision therapies.

    21 min
Ver todo (386)

Acerca de

The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.

Información

  • Creador
    American Society of Hematology
  • Años de actividad
    2019 - 2026
  • Episodios
    386
  • Clasificación
    Apto
  • Copyright
    © 2026 American Society of Hematology

También te podría interesar